Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (161-170 of 210) with videos related to

Pageof 21
Sort By:
Advances in Therapy|February 13, 2026
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French PatientsNicolas Girard, Pauline Macouillard, Danalyn Byng, et al.
Cancers|April 3, 2021
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive PatientsValérie Gounant, Michael Duruisseaux, Ghassen Soussi, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2009
Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary diseaseLaurent Savale, Ari Chaouat, Sylvie Bastuji-Garin, et al.
Frontiers in Oncology|March 7, 2025
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysisGrégoire Justeau, Christos Chouaid, Didier Debieuvre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, et al.
JTO Clinical and Research Reports|January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLCFrancesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
Lung Cancer (Amsterdam, Netherlands)|July 3, 2018
Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)Stefan Andreas, Christos Chouaid, Sarah Danson, et al.
Plos One|January 8, 2019
Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)Christos Chouaid, Mathieu Salaün, Valérie Gounant, et al.
Lung Cancer (Amsterdam, Netherlands)|August 19, 2018
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness studyChristos Chouaid, Sarah Danson, Stefan Andreas, et al.
Journal of Geriatric Oncology|July 27, 2024
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME databaseMathilde Cabart, Loïc Mourey, David Pasquier, et al.
Pageof 21

Showing results (161-170 of 210) with videos related to

Sort By:
Pageof 21
Advances in Therapy|February 13, 2026
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French PatientsNicolas Girard, Pauline Macouillard, Danalyn Byng, et al.
Cancers|April 3, 2021
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive PatientsValérie Gounant, Michael Duruisseaux, Ghassen Soussi, et al.
American Journal of Respiratory and Critical Care Medicine|January 31, 2009
Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary diseaseLaurent Savale, Ari Chaouat, Sylvie Bastuji-Garin, et al.
Frontiers in Oncology|March 7, 2025
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysisGrégoire Justeau, Christos Chouaid, Didier Debieuvre, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 17, 2020
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, et al.
JTO Clinical and Research Reports|January 24, 2025
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLCFrancesca Lucibello, Valérie Gounant, Mihaela Aldea, et al.
Lung Cancer (Amsterdam, Netherlands)|July 3, 2018
Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS)Stefan Andreas, Christos Chouaid, Sarah Danson, et al.
Plos One|January 8, 2019
Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB)Christos Chouaid, Mathieu Salaün, Valérie Gounant, et al.
Lung Cancer (Amsterdam, Netherlands)|August 19, 2018
Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness studyChristos Chouaid, Sarah Danson, Stefan Andreas, et al.
Journal of Geriatric Oncology|July 27, 2024
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME databaseMathilde Cabart, Loïc Mourey, David Pasquier, et al.
Pageof 21